This company has been marked as potentially delisted and may not be actively trading. NYSEARCA:GERM Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM) Get GERM alerts:Sign Up Key Stats Today's Range$19.16▼$19.1650-Day Range$19.16▼$19.1652-Week Range$15.67▼$20.20VolumeN/AAverage Volume1,891 shsMarket Capitalization$9.58 millionAssets Under Management$9.67 millionDividend Yield1.20%Net Expense Ratio0.68%Aggregate RatingN/A ETF Overview The Amplify Treatments, Testing and Advancements ETF (GERM) seeks to provide investment results corresponding to the performance of the Prime Treatments, Testing and Advancements Index. The fund invests in companies engaged in biotechnology, pharmaceuticals, diagnostics, and related industries that support the detection and treatment of infectious diseases. GERM was launched on June 17, 2020, and is managed by Amplify ETFs. The ETF trades on the NYSE Arca under ticker symbol GERM. Prior to January 2024, GERM was managed by ETF Managers Group (ETFMG). Read More Amplify Treatments, Testing and Advancements ETF ExpensesTypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.68%0.57%0.57%0.51%0.53%Other Expenses0.00%0.57%0.55%0.58%0.55%Total Expense0.68%0.73%0.76%0.74%0.73%Fee Waiver0.00%-0.74%-0.64%-0.70%-0.61%Net Expense0.68%0.60%0.63%0.58%0.60% Receive GERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GERM ETF News HeadlinesAmplia Therapeutics Advances Cancer Drug TrialOctober 30, 2024 | markets.businessinsider.comMpox Variant Sparks Global Concern As Europe, China Ramp Up ScreeningAugust 19, 2024 | benzinga.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 17 at 1:00 AM | InvestorPlace (Ad)Amplify ETFs to Liquidate Three ETFsAugust 15, 2024 | finance.yahoo.comTHNR Amplify Weight Loss Drug & Treatment ETFAugust 1, 2024 | seekingalpha.comETFMG Treatments Testing and Advancements ETFFebruary 11, 2024 | thestreet.comSee More Headlines GERM ETF - Frequently Asked Questions What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Treatments, Testing and Advancements ETF investors own include Moderna (MRNA), PayPal (PYPL), Global X Robotics & Artificial Intelligence ETF (BOTZ), Walt Disney (DIS), NVIDIA (NVDA), Tesla (TSLA) and AbbVie (ABBV). Fund Details IssuerAmplify Fund NameAmplify Treatments, Testing and Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GERM Inception Date6/17/2020 Fund ManagerCharles Ragauss, Qiao Duan WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkPrime Treatments, Testing and Advancements Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$9.67 million Average Daily Volume$0.00 Discount/Premium-0.18% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares500,000Beta0.84 Creation Unit50,000 Creation Fee$300.00 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report Top 4 GERM HoldingsInvesco Government & Agency Portfolio 12/31/2031Holding Weight: 99.70%Cash & OtherHolding Weight: 0.30%AstraZeneca PLCHolding Weight: 0.00%Gurnet Point Capital LLCHolding Weight: 0.00%Full Holdings Details This page (NYSEARCA:GERM) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX Goes Public. Here's What Happens To Your IRA.When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Treatments, Testing and Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Treatments, Testing and Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GERM Stock Alerts